



January 21, 2019

Listing Department **BSE LIMITED** P J Towers, Dalal Street, Fort, Mumbai-400 001

Code: 532 321

Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex,

Re.: Press Release.

Mumbai-400 051

Listing Department

Bandra (E),

Dear Sir / Madam,

Please find enclosed a copy of press release dated January 21, 2019 titled "Zydus receives tentative approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.


Thanking you,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

**UPEN H. SHAH** AHMEDABAD **COMPANY SECRETARY** 

Encl.: As above

-----



## Zydus receives tentative approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP

Ahmedabad, 21 January, 2019

Zydus Cadila has received the tentative approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsules (US RLD – NEXIUM). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. The drug is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where stomach makes too much acid.

The group now has 247 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

## About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*

For further information please contact : The Corporate Communications Department Cadila Healthcare Limited 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India. Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com

CIN-L24230GJ1995PLC025878